Aytu BioScience, Inc., a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia. It also offers MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. In addition, the company provides MiOXSYS analyzer, a portable lightweight desktop platform that is used in clinical or research laboratory or near a patient care area; and MiOXSYS disposable sensors. The company is based in Englewood, Colorado.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone720-437-6580
Debt
Current Ratio1.92
Quick Ratio1.55
Price-To-Earnings
Sales & Book Value
Annual Sales$3.66 million
Price / Sales2.50
Price / Cash FlowN/A
Price / Book0.14
Profitability
Net Income$-10,180,000.00
Net Margins-233.14%
Return on Assets-61.21%
Miscellaneous
Employees57
OptionableNot Optionable
Aytu Bioscience (NASDAQ:AYTU) Frequently Asked Questions
What is Aytu Bioscience's stock symbol?
Aytu Bioscience trades on the NASDAQ under the ticker symbol "AYTU."
When did Aytu Bioscience's stock split? How did Aytu Bioscience's stock split work?
Aytu Bioscience shares reverse split on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 28th 2017. An investor that had 100 shares of Aytu Bioscience stock prior to the reverse split would have 5 shares after the split.
How were Aytu Bioscience's earnings last quarter?
Aytu Bioscience Inc (NASDAQ:AYTU) posted its earnings results on Wednesday, November, 7th. The company reported ($1.96) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.45) by $0.51. The business earned $1.43 million during the quarter, compared to analyst estimates of $1.33 million. Aytu Bioscience had a negative return on equity of 126.47% and a negative net margin of 233.14%. View Aytu Bioscience's Earnings History.
When is Aytu Bioscience's next earnings date?
What price target have analysts set for AYTU?
1 brokerages have issued 12 month price targets for Aytu Bioscience's stock. Their predictions range from $10.00 to $10.00. On average, they expect Aytu Bioscience's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 843.4% from the stock's current price. View Analyst Price Targets for Aytu Bioscience.
What is the consensus analysts' recommendation for Aytu Bioscience?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aytu Bioscience in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aytu Bioscience.
Has Aytu Bioscience been receiving favorable news coverage?
Press coverage about AYTU stock has been trending positive this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aytu Bioscience earned a media sentiment score of 2.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an impact on the company's share price in the near future.
Who are some of Aytu Bioscience's key competitors?
Some companies that are related to Aytu Bioscience include Neurotrope (NTRP), Zosano Pharma (ZSAN), Akari Therapeutics (AKTX), Oncomed Pharmaceuticals (OMED), Eyenovia (EYEN), IMMURON LTD/S (IMRN), Agile Therapeutics (AGRX), Trillium Therapeutics (TRIL), Sunesis Pharmaceuticals (SNSS), Q BioMed (QBIO), Provectus Biopharmaceuticals (PVCT), Ceapro (CRPOF), OvaScience (OVAS), ESSA Pharma (EPIX) and Acerus Pharmaceuticals (TRLPF).
Who are Aytu Bioscience's key executives?
Aytu Bioscience's management team includes the folowing people:
- Mr. Joshua R. Disbrow, Chairman & CEO (Age 44)
- Mr. David A. Green, CFO, Sec. & Treasurer (Age 56)
- Mr. Jarrett T. Disbrow, Chief Operating Officer (Age 44)
How do I buy shares of Aytu Bioscience?
Shares of AYTU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aytu Bioscience's stock price today?
One share of AYTU stock can currently be purchased for approximately $1.06.
How big of a company is Aytu Bioscience?
Aytu Bioscience has a market capitalization of $7.96 million and generates $3.66 million in revenue each year. The company earns $-10,180,000.00 in net income (profit) each year or ($27.94) on an earnings per share basis. Aytu Bioscience employs 57 workers across the globe.
What is Aytu Bioscience's official website?
How can I contact Aytu Bioscience?
Aytu Bioscience's mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-437-6580 or via email at [email protected]
MarketBeat Community Rating for Aytu Bioscience (NASDAQ AYTU)
MarketBeat's community ratings are surveys of what our community members think about Aytu Bioscience and other stocks. Vote "Outperform" if you believe AYTU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AYTU will underperform the S&P 500 over the long term. You may vote once every thirty days.
